InvestorsHub Logo
Followers 7
Posts 410
Boards Moderated 0
Alias Born 06/04/2014

Re: runncoach post# 4521

Monday, 05/01/2017 7:03:33 AM

Monday, May 01, 2017 7:03:33 AM

Post# of 21531
"Further analysis of the data from the Phase 2 -202 Study is ongoing, and Neurotrope plans to present more data and analyses from this study at future medical conferences. Once all of the data and analyses have been reviewed, the Company plans to meet with the Food and Drug Administration (FDA) to address the clinical and regulatory path forward for Bryostatin-1. "
 
A higher SIB score would have made that "path forward" an easier road to travel. 


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News